MGNX Stock Forecast: MacroGenics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for MacroGenics, Inc. is $8.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 87 of 100 as at 18 Nov 2026 — inside the top quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores MacroGenics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MGNX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MGNX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | B. Riley Securities | Maintains | Buy | $9.00 → $11 |
| 20 Apr 2026 | Barclays | Maintains | Overweight | $4.00 → $6.00 |
| 10 Apr 2026 | B. Riley Securities | Upgrade | Buy | — |
| 10 Mar 2026 | Barclays | Maintains | Overweight | — |
| 3 Nov 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 17 Sept 2025 | Barclays | Assumes | Overweight | $3.00 |
| 15 Aug 2025 | Leerink Partners | Maintains | Outperform | — |
| 20 May 2025 | B. Riley Securities | Maintains | Neutral | — |
| 14 May 2025 | Barclays | Maintains | Overweight | — |
| 14 May 2025 | Stifel | Maintains | Hold | — |
| 25 Mar 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 7 Nov 2024 | JMP Securities | Downgrade | Market Perform | — |
| 6 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 18 Sept 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 21 Aug 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 15 Aug 2024 | Citigroup | Maintains | Buy | — |
| 7 Aug 2024 | BMO Capital | Maintains | Market Perform | — |
| 1 Aug 2024 | BTIG | Downgrade | Neutral | — |
| 1 Aug 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 31 July 2024 | B. Riley Securities | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MGNX.
This page is one stock. Monday covers all of them.
MGNX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MGNX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, MacroGenics, Inc. returned +39.4% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MGNX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.9×
- Price / book
- 5.2×
- EV / EBITDA
- —
Cheaper than 68% of US stocks
Cheaper than 18% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 54.1%
- Operating margin
- −48.8%
- Net margin
- —
Higher than 67% of US stocks
Higher than 18% of US stocks
- Return on equity
- −284.5%
- Return on assets
- −14.6%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 23% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MacroGenics, Inc. has a market value of $131.0M.
Revenue in the twelve months to 30 June 2026: $167.7M. The latest quarter grew 47.6% year on year.
Net income over the same four quarters: −$14.6M, a −8.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$65.5M.
MacroGenics, Inc. employs 293 people — $572K of revenue per employee.
Data provided by Twelve Data
MGNX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MGNX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own MacroGenics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MGNX
What is the MGNX stock price forecast for 2026-2027?
The median 12-month analyst price target for MacroGenics, Inc. is $8.5, with estimates ranging from $4 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MGNX stock a buy right now?
Of the 7 analysts covering MacroGenics, Inc., 3 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MacroGenics, Inc. 87 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MGNX?
As at 18 Nov 2026, MacroGenics, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).
Will MGNX stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts is $8.5, and Ticker Nerd's factor model ranks MacroGenics, Inc. 87 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MGNX stock forecast for 2030?
No analyst covering MacroGenics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $11 over the next 12 months.
How has MGNX stock performed over the past year?
MacroGenics, Inc. returned +39.4% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does MacroGenics, Inc. do?
MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics for cancer. Its current portfolio centers on advanced biologics platforms, including antibody-drug conjugates, bispecific checkpoint antibodies, and next-generation T-cell engagers, which support a pipeline of product candidates in clinical testing.
About MacroGenics, Inc.
MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics for cancer. Its current portfolio centers on advanced biologics platforms, including antibody-drug conjugates, bispecific checkpoint antibodies, and next-generation T-cell engagers, which support a pipeline of product candidates in clinical testing. The company’s work includes therapies designed to target specific tumor markers and modulate immune responses across a range of oncology settings. MacroGenics also maintains collaborations with other biotechnology and pharmaceutical companies to support development across its programs. Headquartered in Rockville, Maryland, MacroGenics plays a specialized role in the oncology market by advancing precision antibody technologies intended for use in difficult-to-treat cancers.
CEO Mr. Eric Blasius Risser · 293 employees · United States · https://www.macrogenics.com